Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Staphylococcus aureus bivalent (types 5 and 8) conjugate vaccine - Nabi

Drug Profile

Staphylococcus aureus bivalent (types 5 and 8) conjugate vaccine - Nabi

Alternative Names: S. aureus type 5 & 8 capsular polysaccharide conjugate vaccine - Nabi; Staphylococcus aureus polysaccharide conjugate vaccine bivalent - Nabi; Nabi-StaphVAX; StaphVAX-Bivalent

Latest Information Update: 26 Mar 2007

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nabi Biopharmaceuticals; National Institutes of Health (USA)
  • Class Bacterial vaccines; Conjugate vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Staphylococcal infections

Most Recent Events

  • 31 Mar 2006 Nabi Biopharmaceuticals has resumed development of the Staphylococcus aureus vaccine conjugate following a positive review by an outside advisory panel
  • 04 Nov 2005 Nabi Biopharmaceuticals withdrawn its MAA for StaphVAX® for the prevention of Staphylococcal infections in patients with end-stage renal disease in the European Union
  • 04 Nov 2005 Clinical data from a media release have been added to the Bacterial Infections immunogenicity section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top